Testing effectiveness (Phase 2)Looking for participantsNCT06696183
What this trial is testing
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Who this might be right for
AML - Acute Myeloid Leukemia
Technische Universität Dresden 60